

سامية محمد مصطفى



شبكة المعلومات الجامعية

بسم الله الرحمن الرحيم



سامية محمد مصطفى



شبكة المعلومات الجامعية



شبكة المعلومات الجامعية التوثيق الالكتروني والميكرو فيلم



سامية محمد مصطفى



شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم


قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



سامية محمد مصطفى



شبكة المعلومات الجامعية



بعض الوثائق الأصلية تالفة



سامية محمد مصطفى



شبكة المعلومات الجامعية



بالرسالة صفحات لم ترد بالأصل



**DETECTION OF BCL TRANSLOCATIONS IN NON-HODGKIN'S
LYMPHOMA AND ITS CORRELATION TO NATURAL
BEHAVIOUR OF THE DISEASE AS WELL AS TREATMENT
RESPONSE**

Thesis

Submitted for partial fulfillment of master degree in radiotherapy &
nuclear medicine

By


Mohamed Abouelfetouh El-Sayed Shehata

M.B.,B.Ch.,

Supervisors



Prof. Dr. Kamal EL-Ghamrawy
Chairman and Prof. of Clinical Oncology
Kaser EL-Aini Faculty of Medicine
Cairo University



Dr. Tarek Hashem
Ass. Prof. of Clinical Oncology
Faculty of Medicine , Menoufiya University



Dr. Manal EL Masry
Ass. Prof. of Clinical Pathology
Kaser EL-Aini Faculty of Medicine
Cairo University



Dr. Khaled Kamal EL-Deen Abd EL-Aziz
Lecturer of Clinical Oncology
Faculty of Medicine , Menoufiya University

**Faculty of Medicine
Menoufiya University
2000**

B

10507

LIST OF CONTENTS

	Page
INTRODUCTION -----	1
REVIEW OF LITERATURE:	
I.BIOLOGY-----	5
II.CLASSIFICATION OF NHL-----	9
III. STAGING OF NHL-----	14
IV. GENE TRANSLOCATION IN NHL -----	17
V. PROGNOSTIC FACTORS OF NHL -----	21
VI. TREATMENT OF NHL -----	31
VII. APOPTOSIS AND ITS RELATED GENES -----	43
VIII. ROLE OF BCL-X & BCL-2 IN PROTECTION AGAINST CHEMOTHERAPY -----	49
IX. BCL-X IN NHL -----	52
MATERIAL & METHOD -----	55
RESULTS -----	72
DISCUSSION -----	114
SUMMARY -----	123
REFERENCES -----	125
ARABIC SUMMARY	

LIST OF TABLES

Table No.	Title	Page
Table 1	Working Formulation Classification for NHL	11
Table 2	Updated Kiel classification	12
Table 3	Revised European-American Classification of Lymphoid Neoplasm	13
Table 4	Staging of NHL: required and suggested evaluation procedures	15
Table 5	Staging system of non-Hodgkin's lymphoma	16
Table 6	Prognostic factors for survival in international index patients	25
Table 7	Comparative structure of the main members of the Bcl-2 family	48
Table 8	PCR reaction mixture for DNA samples used for detection of Bcl-xL	65
Table 9	PCR reaction mixture for DNA samples used for detection of Bcl-xS	66
Table 10	Patient characteristics	77
Table 11	Bcl-xL expression in relation to sex	78
Table 12	Bcl-xL expression in relation to age	79
Table 13	Bcl-xL expression in relation to pathology	80
Table 14	Bcl-xL expression in relation to stage	82
Table 15	Bcl-xL expression in relation to tumor size	84
Table 16	Bcl-xL expression in relation to number of extranodal sites	86
Table 17	Bcl-xL expression in relation to B-symptoms	88
Table 18	Bcl-xL expression in relation to BM infiltration	90
Table 19	Relationship between Bcl-xL expression and international prognostic index category	92
Table 20	Bcl-xL expression in relation to treatment outcome	94
Table 21	Bcl-xL expression in relation to early response to treatment	96
Table 22	Bcl-xL expression in relation to disease free survival	98

Table No.	Title	Page
Table 23	Bcl-xL expression in relation to overall survival	100
Table 24	Bcl-xL expression before treatment in relation to Bcl-xL after treatment	102
Table 25	Correlation between patient characteristics and treatment outcome	104
Table 26	Multivariate stepwise regression analysis of prognostic factors in relation to response	106
Table 27	Multivariate stepwise regression analysis of prognostic factors in relation to overall survival	107
Table 28	Multivariate stepwise regression analysis of prognostic factors as regard to disease-free survival	108

LIST OF FIGURES

Figure No.	Title	Page
Fig. 1	Hypothetical scheme of lymphocyte differentiation.	8
Fig. 2	RNA extraction from pellet of cells.	61
Fig. 3	Mechanism of amplification.	68
Fig. 4	Bcl-xL in relation to histologic subtypes.	81
Fig. 5	Bcl-xL expression in relation to Ann Arbor Stage.	83
Fig. 6	Bcl-xL expression in relation to tumor size.	85
Fig. 7	Bcl-xL expression before treatment in relation to number of extranodal sites.	78
Fig. 8	Bcl-xL expression before treatment in relation to B symptoms.	89
Fig. 9	Bcl-xL expression in relation to bone marrow infiltration	91
Fig. 10	Bcl-xL expression in relation to international prognostic index categories.	93
Fig. 11	Bcl-xL expression in relation to treatment outcome.	95
Fig. 12	Bcl-xL expression in relation to time to CR.	97
Fig. 13	Disease free survival for Bcl-xL positive and Bcl-xL negative patients.	99
Fig. 14	Overall survival for Bcl-xL positive and Bcl-xL negative patients.	101
Fig. 15	Bcl-xL before treatment and after treatment.	103
Fig. 16-20	Pictures of RTPCR	109-113

